Fibrinolytic drugs prevent pericardial adhesions in the rabbit.

Abstract

Epicardial adhesions are believed to form secondarily to impaired pericardial fibrinolytic activity. This activity was reconstituted in a rabbit pericardial adhesion model with single doses of the fibrinolytic agents tissue plasminogen activator (t-PA), t-PA analog (Fb-Fb-CF), and streptokinase (SK), resulting in reductions in the extent and tenacity of adhesion formation. Adhesions of the median strip of the anterior cardiac surface were reduced in area from 89% (n = 22) in controls, to 28% (n = 5) by treatment with Fb-Fb-CF (0.94 mg), and to 49% (n = 7) by treatment with SK (93,750 IU). A modified fabric of oxidized regenerated cellulose (mTC7) used to deliver the agent to the cardiac surface did not interfere with the activity of these agents (Fb-Fb-CF 19%, n = 14; SK 33%, n = 7). t-PA (0.94 mg) was also found to reduce adhesion formation in combination with mTC7 (4%, n = 4), although the appearance of significant postoperative bruising and bleeding resulted in a decision to terminate the treatment of further animals with t-PA with and without mTC7. Postoperative bruising, bleeding, and swelling, to a lesser extent, were associated with SK and Fb-Fb-CF. Despite the efficacy of the these fibrinolytic drugs further work is required to assess their safety before they are used clinically.

• Authors: D M Wiseman, L Kamp, C B Linsky, R F Jochen, R H Pang, P M Scholz
• Journal: The Journal of surgical research (J Surg Res) Vol. 53 Issue 4 Pg. 362-8 (Oct 1992) ISSN: 0022-4804 [Print] United States
• PMID: 1405617 (Publication Type: Journal Article)

Chemical References

• Drug Carriers
• Fibrinolytic Agents
• Peptide Fragments
• Recombinant Proteins
• Staphylococcal Protein A
• Cellulose
• Streptokinase
• Tissue Plasminogen Activator
• tissue plasminogen activator-(staphylococcal A, B fragment) dimer

Topics

• Animals
• Cellulose
• Drug Carriers
• Female
• Fibrinolytic Agents (administration & dosage, therapeutic use)
• Heart Diseases (prevention & control)
• Male
• Peptide Fragments (administration & dosage, therapeutic use)
• Pericardium
• Postoperative Complications
• Rabbits
• Recombinant Proteins (administration & dosage, therapeutic use)
• Staphylococcal Protein A (administration & dosage, therapeutic use)
• Streptokinase (administration & dosage, therapeutic use)
• Tissue Adhesions (prevention & control)
• Tissue Plasminogen Activator (administration & dosage, therapeutic use)